The mammalian target of rapamycin (mTOR) is a protein kinase that controls cellular
metabolism, catabolism, immune responses, autophagy, survival, proliferation, and …

Biomolecule-based nanostructures are inherently multifunctional and harbour diverse
biological activities, which can be explored for cancer nanomedicine. The supramolecular …

Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

Nanomedicines are now considered as the new-generation medication in the current era
mainly because of their features related to nano size. The efficacy of many drugs in their …

Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr)
protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein …

Nanomaterials are increasingly used as drug carriers for cancer therapy. Nanomaterials
also appeal to researchers in the areas of cancer diagnosis and biomarker discovery …

Clinical Translation of Nanomedicine | Chemical Reviews ACS ACS Publications C&EN CAS
Find my institution Log In Chemical Reviews ACS Publications. Most Trusted. Most Cited. Most …

Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth
and metabolism in response to nutrients, growth factors and cellular energy levels, and it is …

Cancer nanotheranostics aims to combine imaging and therapy of cancer through use of
nanotechnology. The ability to engineer nanomaterials to interact with cancer cells at the …

Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic
endoplasmic reticulum (ER) stress, which is adaptively managed by the unfolded protein …